Nano Pharmaceuticals
Market Cap
₹109 ₹109 Cr.
P/E
0.00
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.44
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
10.30 %
Institutions
Institutions
-
Market cap
Market cap
109 Cr
No. of Shareholders
No. of Shareholders
8,632
OPM (%)
OPM (%)
-35.17 %
PE
PE
-
Prom Holding
Prom Holding
32.99 %
ROCE (%)
ROCE (%)
-29.92
ROE (%)
ROE (%)
-
Sales
Sales
25.34 Cr
  • Pharmaids Pharma
  • Aayush Wellness
  • Vaishali Pharma

Nothing to show here

This view can't be shown right now. We're continuously expanding and updating coverage across companies, so please check back again soon.

Nothing to show here

This view can't be shown right now. We're continuously expanding and updating coverage across companies, so please check back again soon.

Price Range

See where the stock is trading versus its 52-week high and low.

Low
26
52W Range
High
54
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

5 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

2 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Pharmaids Pharmaceuticals Ltd. Business

Pharmaids Pharmaceuticals Ltd, founded in 1991 in Hyderabad, Andhra Pradesh, specializes in manufacturing herbal cough syrups, cold tablets, pain reliever tablets, active charcoal tablets, joint pain ointments, and more.

Pharmaids Pharma major competitors are Asston Pharma, Makers Laboratories, Tyche Industries, Himalaya Nutravedics, Veerhealth Care, Concord Drugs, Sotac Pharmaceutical.
Market Cap of Pharmaids Pharma is ₹106 Crs.
While the median market cap of its peers are ₹106 Crs.

Pharmaids Pharma seems to be less financially stable compared to its competitors.
Altman Z score of Pharmaids Pharma is 2.19 and is ranked 8 out of its 8 competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material